Alireza Ghoreifi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alireza Ghoreifi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Potretzke
Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Alberto Breda
Unit of Uro-oncology and Kidney Transplant, Department of Urology, Puigvert Foundation, Universitat Autònoma de Barcelona (UAB), 08025 Barcelona, Spain
1 shared publication - Andrea Mari
University of Florence, Italy
1 shared publication Ankeet M. Shah
Department of Urology, Duke University Medical Center, Durham, USA
1 shared publication- Axel Heidenreich
Department of Urology, Urologic Oncology, Robot‐Assisted and Specialized Urologic Surgery University of Cologne Cologne Germany
1 shared publication - Benjamin Pradere
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- 2 October 2026
- Published by Springer Nature in Current Urology Reports
- Vol. 27 (1) , 53
Imaging in Upper Tract Urothelial Carcinoma: Diagnostic Accuracy of Current Modalities for Local Tumor Staging
- 2 October 2026
- Published by Springer Nature in Current Urology Reports
- Vol. 27 (1) , 53
Imaging in Upper Tract Urothelial Carcinoma: Diagnostic Accuracy of Current Modalities for Local Tumor Staging
- 1 November 2024
- Published by SAGE Publications in Journal of Endourology
- Vol. 38 (11) , 1156-1163
Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma
Background: Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy (RNU) pathology. Methods: In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses. Results: Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p = 0.007). Downgrading was comparable across all tumor locations. On multivariate analyses, middle ureteral location was significantly associated with a low probability of grade concordance (odds ratio [OR] 0.59; 95% confidence interval [CI], 0.35–1.00; p = 0.049) and an increased risk of upgrading (OR 2.80; 95% CI, 1.20–6.52; p = 0.017). The discordance did not vary regardless of caliceal location, including the lower calyx. Conclusions: Middle ureteral tumors diagnosed to be low grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counseling and shared decision making regarding the choice of kidney sparing vs RNU.
- 1 November 2024
- Published by SAGE Publications in Journal of Endourology
- Vol. 38 (11) , 1156-1163
Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma
Background: Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy (RNU) pathology. Methods: In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses. Results: Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p = 0.007). Downgrading was comparable across all tumor locations. On multivariate analyses, middle ureteral location was significantly associated with a low probability of grade concordance (odds ratio [OR] 0.59; 95% confidence interval [CI], 0.35–1.00; p = 0.049) and an increased risk of upgrading (OR 2.80; 95% CI, 1.20–6.52; p = 0.017). The discordance did not vary regardless of caliceal location, including the lower calyx. Conclusions: Middle ureteral tumors diagnosed to be low grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counseling and shared decision making regarding the choice of kidney sparing vs RNU.